HIV protease inhibitors as new treatment options for Kaposi's sarcoma

Drug Resistance Updates

Volumn 6, Issue 4, 2003, Pages 173-181

  Barillari, Giovanni ^a   Sgadari, Cecilia ^a   Toschi, Elena ^a   Monini, Paolo ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Angiogenesis; Cell invasion; HIV protease inhibitors; Kaposi's sarcoma; Matrix metalloproteinases

Indexed keywords

ANTIRETROVIRUS AGENT; GELATINASE A; INDINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; CELL INVASION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; KAPOSI SARCOMA; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION;

EID: 0141631420     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(03)00060-8     Document Type: Article

References (81)

1. Albini, A., Fontanini, G., Masiello, L., Tacchetti, C., Bigini, D., Luzzi, P., Noonan, D.M., Stetler-Stevenson, W.G., 1994. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supematants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS8, 1237-1244.
2. Andersson, J., Fehniger, T.E., Patterson, B.K., et al., 1998. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS12, F123-F129.
3. Ascherl, G., Hohenadl, C., Schatz, O., et al., 1999. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood93, 4232-4241.
4. Ascherl, G., Sgadari, C., Bugarini, R., Bogner, J., Schatz, O., Ensoli, B., Stürzl, M., 2001. Serum concentrations of fibroblast growth factor-2 are increased in HIV type 1-infected patients and inversely related with survival probability. AIDS Res. Hum. Retroviruses.17, 1035-1039.
5. Autran, B., Carcelain, G., Li, T.S., Blanc, C., Mathez, D., Tubiana, R., Katlama, C., Debre, P., Leibowitch, J., 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science277, 112-116.
6. Barillari, G., Ensoli, B., 2002. Angiogenic effects of extracellular human immunodeficiency vires type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin. Microbiol. Rev. 15, 310-326.
7. Benelli, R., Adatia, R., Ensoli, B., Stetler-Stevenson, W.G., Santi, L., Albini, A., 1994. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol. Res.6, 251-257.
8. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., Hanahan, D., 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science284, 808-812.
9. Bohler, T., Walcher, J., Holzl-Wenig, G., Geiss, M., Buchholz, B., Linde, R., Debatin, K.M., 1999. Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. AIDS13, 779-789.
10. Boivin, G., Gaudreau, A., Toma, E., Lalonde, R., Routy, J.P., Murray, G., Handfield, J., Bergeron, M.G., 1999. Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Antimicrob. Agents Chemother.43, 377-380.
11. Boshoff, C., Weiss, R., 2002. AIDS-related malignancies. Nat. Rev. Cancer2, 373-382.
12. Bramhall, S.R., Hallissey, M.T., Whiting, J., et al., 2002. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer86, 1864-1870.
13. Brand, K., Baker, A.H., Perez-Canto, A., Possling, A., Sacharjat, M., Geheeb, M., Arnold, W., 2000. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res.15, 5723-5730.
14. Brenner, B., Rakowsky, E., Katz, A., Gutman, H., Sulkes, A., Schacter, J., Fenig, E., 1999. Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines. Int. J. Oncol.14, 1097-1102.
15. Carmeliet, P., Jain, R.K., 2000. Angiogenesis in cancer and other diseases. Nature407, 249-257.
16. Caron, M., Auclair, M., Vigouroux, C., Glorian, M., Forest, C., Capeau, J., 2001. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance 1. Diabetes50, 1378-1388.
17. Carpenter, C.C., Cooper, D.A., Fischl, M.A., et al., 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society USA Panel 2. JAMA283, 381-390.
18. Cassone, A., De Bernardis, F., Torosantucci, A., Tacconelli, E., Tumbarello, M., Cauda, R., 1999. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180, 448-453.
19. Cattelan, A.M., Calabro, M.L., Aversa, S.M., Zanchetta, M., Meneghetti, F., De Rossi, A., Chieco-Bianchi, L., 1999. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer35, 1809-1815.
20. Chao, S.C., Lee, J.Y., Tsao, C.J., 2001. Treatment of classical type Kaposi's sarcoma with paclitaxel. Anticancer Res.21, 571-573.
21. Cianfrocca, M., Cooley, T.P., Lee, J.Y., Rudek, M.A., Scadden, D.T., Rather, L., Pluda, J.M., Figg, W.D., Krown, S.E., Dezube, B.J., 2002. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol.20, 153-159.
22. Costagliola, D., Mary-Krause, M., 1995. Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodeficience Humaine. Lancet346, 578.
23. Coussens, L.M., Fingleton, B., Matrisian, L.M., 2002. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science295, 2387-2392.
24. Douek, D.C., McFarland, R.D., Keiser, P.H., et al., 1998. Changes in thymic function with age and during the treatment of HIV infection. Nature396, 690-695.
25. Dowell, P., Flexner, C., Kwiterovich, P.O., Lane, M.D., 2000. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J. Biol. Chem.275, 41325-41332.
26. Drewe, J., Gutmann, H., Fricker, G., Torok, M., Beglinger, C., Huwyler, J., 1999. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol.57, 1147-1152.
27. Egeblad, M., Werb, Z., 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer2, 161-174.
28. Ensoli, B., Gendelman, R., Markham, P., Fiorelli, V., Colombini, S., Raffeld, M., Cafaro, A., Chang, H.K., Brady, J.N., Gallo, R.C., 1994a. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature371, 674-680.
29. Ensoli, B., Markham, P., Kao, V., Barillari, G., Fiorelli, V., Gendelman, R., Raffeld, M., Zon, G., Gallo, R.C., 1994b. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth facton A novel strategy for the therapy of KS. J. Clin. Invest.94, 1736-1746.
30. Ensoli, B., Sgadari, C., Barillari, G., Sirianni, M.C., Sturzl, M., Monini, P., 2001a. Biology of Kaposi's sarcoma. Eur. J. Cancer37, 1251-1269.
31. Ensoli, B., Sturzl, M., Monini, P., 2001b. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv. Cancer Res.81, 161-200.
32. Evans, J.D., Stark, A., Johnson, C.D., Daniel, F., Carmichael, J., Buckels, J., Imrie, C.W., Brown, P., Neoptolemos, J.P., 2001. A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer85, 1865-1870.
33. Falardeau, P., Champagne, P., Poyet, P., Hariton, C., Dupont, E., 2001. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol.28, 620-625.
34. Ferreras, M., Felbor, U., Lenhard, T., Olsen, B.R., Delaisse, J., 2000. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett.486, 247-251.
35. Flexner, C., 1998. HIV-protease inhibitors. N. Engl. J. Med.338, 1281-1292.
36. Flexner, C.W., Piscitelli, S.C., 2002. Concentration-targeted therapy and the future of HIV management. AIDS16, S1-S3.
37. Fong, T.A., Shawver, L.K., Sun, L., et al., 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res.59, 99-106.
38. Gaedicke, S., Firat-Geier, E., Constantiniu, O., Lucchiari-Hartz, M., Freudenberg, M., Galanos, C., Niedermann, G., 2002. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res.62, 6901-6908.
39. Garbisa, S., Biggin, S., Cavallarin, N., Sartor, L., Benelli, R., Albini, A., 1999. Tumor invasion: molecular shears blunted by green tea. Nat. Med.5, 1216.
40. Glesby, M.J., Hoover, D.R., Weng, S., Graham, N.M., Phair, J.P., Detels, R., Ho, M., Saah, A.J., 1996. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J. Infect. Dis.173, 1477-1480.
41. Gorochov, G., Neumann, A.U., Kereveur, A., et al., 1998. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nat. Med.4, 215-221.
42. Gruber, A., Wheat, J.C., Kuhen, K.L., Looney, D.J., Wong-Staal, F., 2001. Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. J. Biol. Chem.276, 47840-47843.
43. Hellerstein, M., Hanley, M.B., Cesar, D., et al., 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med.5, 83-89.
44. Hernandez-Barrantes, S., Toth, M., Bernardo, M.M., Yurkova, M., Gervasi, D.C., Raz, Y., Sang, Q.A., Fridman, R., 2000. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem.275, 12080-12089.
45. Hotary, K.B., Yana, I., Sabeh, F., Li, X.Y., Holmbeck, K., Birkedal-Hansen, H., Allen, E.D., Hiraoka, N., Weiss, S.J., 2002. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J. Exp. Med. 195, 295-308.
46. Humphrey, R.W., O'Brien, T.R., Newcomb, F.M., et al., 1996. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood88, 297-301.
47. International Collaboration on HIV and Cancer, 2000. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl. Cancer Inst. 92, 1823-1830.
48. Jiang, Y., Wang, M., Celiker, M.Y., Liu, Y.E., Sang, Q.X., Goldberg, I.D., Shi, Y.E., 2001. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res.61, 2365-2370.
49. Koivunen, E., Arap, W., Valtanen, H., et al., 1999. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768-774.
50. Krown, S.E., 2001. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr. Opin. Oncol.13, 374-381.
51. Lebbè, C., Blum, L., Pellet, C., Blanchard, G., Verola, O., Morel, P., Danne, O., Calvo, F., 1998. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS12, F45-F49.
52. Levine, A.M., Tulpule, A., 2001. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur. J. Cancer37, 1288-1295.
53. Lichtenstein, K.A., Ward, D.J., Moorman, A.C., et al., 2001. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS15, 1389-1398.
54. Lo, T.C., Salzman, F.A., Smedal, M.I., Wright, K.A., 1980. Radiotherapy for Kaposi's sarcoma. Cancer45, 684-687.
55. Marchell, N., Alster, T.S., 1997. Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser. Dermatol. Surg.23, 973-975.
56. McQuibban, G.A., Gong, J.H., Tam, E.M., McCulloch, C.A., Clark-Lewis, I., Overall, C.M., 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science289, 1202-1206.
57. Mocroft, A., Youle, M., Gazzard, B., Morcinek, J., Halai, R., Phillips, A.N., 1996. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS10, 1101-1105.
58. Monini, P., Colombini, S., Sturzl, M., et al., 1999. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood93, 4044-4058.
59. Murata, H., Hruz, P.W., Mueckler, M., 2000. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem.275, 20251-20254.
60. Nagase, H., Woessner Jr., J.F., 1999. Matrix metalloproteinases. J. Biol. Chem.274, 21491-21494.
61. Nguyen, A.T., Gagnon, A., Angel, J.B., Sorisky, A., 2000. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS14, 2467-2473.
62. Northfelt, D.W., Dezube, B.J., Thommes, J.A., et al., 1998. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 16, 2445-2451.
63. Pajonk, F., Himmelsbach, J., Riess, K., Sommer, A., McBride, W.H., 2002. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res.62, 5230-5235.
64. Piccinini, M., Rinaudo, M.T., Chiapello, N., Ricotti, E., Baldovino, S., Mostert, M., Tovo, P.A., 2002. The human 26S proteasome is a target of antiretroviral agents. AIDS16, 693-700.
65. Ren, S., Lien, E.J., 1998. Development of HIV protease inhibitors: a survey. In: Jucker, E. (Ed.), Progress in Drug Research, vol. 51. Birkhauser Verlag, Basel, Switzerland, pp. 4-30.
66. Riddle, T.M., Schildmeyer, N.M., Phan, C., Fichtenbaum, C.J., Hui, D.Y., 2002. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J. Lipid Res.43, 1458-1463.
67. Roberts, N.A., Martin, J.A., Kinchington, D., et al., 1990. Rational design of peptide-based HIV proteinase inhibitors. Science248, 358-361.
68. Samaniego, F., Markham, P.D., Gendelman, R., et al., 1998. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am. J. Pathol.152, 1433-1443.
69. Sgadari, C., Toschi, E., Palladino, C., et al., 2000. Mechanism of paclitaxel activity in Kaposi's sarcoma. J. Immunol.165, 509-517.
70. Sgadari, C., Barillari, G., Toschi, E., et al., 2002. HIV protease inhibitors are potent anti-angiogenic molecules and promote recession of Kaposi sarcoma. Nat. Med.8, 225-232.
71. Sheu, B.C., Hsu, S.M., Ho, H.N., Lien, H.C., Huang, S.C., Lin, R.H., 2001. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res.61, 237-242.
72. Sirianni, M.C., Vincenti, L., Topino, S., et al., 2002. NK cell activity controls human herpesvirus 8 latent infection and is restored upon HAART in AIDS patients with regressing Kaposi's sarcoma. Eur. J. Immunol.32, 2711-2720.
73. Sloand, E.M., Kumar, P.N., Kim, S., Chaudhuri, A., Weichold, F.F., Young, N.S., 1999. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood94, 1021-1027.
74. Stetler-Stevenson, W.G., 1999. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest. 103, 1237-1241.
75. Toschi, E., Barillari, G., Sgadari, C., et al., 2001. Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Mol. Biol. Cell12, 2934-2946.
76. Tovo, P.A., 2000. Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects. AIDS14, 743-744.
77. Tulpule, A., Scadden, D.T., Espina, B.M., Cabriales, S., Howard, W., Shea, K., Gill, P.S., 2000. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 18, 716-723.
78. Volker, C., Lupas, A.N., 2002. Molecular evolution of proteasomes. Curr. Top. Microbiol. Immunol.268, 1-22.
79. Weichold, F.F., Bryant, J.L., Pati, S., Barabitskaya, O., Gallo, R.C., Reitz Jr., M.S., 1999. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J. Hum. Virol.2, 261-269.
80. Wilkinson, J., Cope, A., Gill, J., et al., 2002. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J. Virol.76, 2634-2640.
81. Zhong, D.S., Lu, X.H., Conklin, B.S., Lin, P.H., Lumsden, A.B., Yao, Q., Chen, C., 2002. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler. Thromb. Vasc. Biol.22, 1560-1566.